ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    J

    Dr Joshua Reuss, MD

    Medical professional dedicated to sharing knowledge and insights through educational videos.

    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    BEAMION secondary efficacy

    Joshua Reuss, MD
    Lung Cancer
    Dr. Joshua Reuss discusses the design of the BEAMION Lung trial of zongertinib in HER2m NSCLC (Video 1/3)

    Dr. Joshua Reuss discusses the design of the BEAMION Lung trial of zongertinib in HER2m NSCLC (Video 1/3)

    BEAMION efficacy

    Joshua Reuss, MD
    Lung Cancer